<DOC>
	<DOCNO>NCT02310802</DOCNO>
	<brief_summary>The primary objective study assess increase clinical pregnancy rate administration range single oral dos OBE001 , oral oxytocin antagonist , compare placebo .</brief_summary>
	<brief_title>OBE001 Phase 2 Dose-finding Study Versus Placebo Women Undergoing Embryo Transfer Context IVF-ICSI</brief_title>
	<detailed_description>The study prospective , dose-finding , randomise , parallel group , double-blind , placebo-controlled study investigate efficacy safety oxytocin receptor antagonist OBE001 240 woman undergo embryo transfer follow IVF ICSI . The four-arm study ( OBE001 dose 1 , dose 2 , dose 3 , placebo ) design allow evaluation possible dose-dependent pattern action OBE001 , simultaneously , comparison active compound placebo regard efficacy safety .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<criteria>Key Inclusion Criteria 1 . Women medically indicate IVF ICSI use oocyte . 2 . GnRH antagonist protocol , single injection hCG trigger final follicular maturation luteal phase support vaginal micronized progesterone . 3 . Evidence uterine contraction transvaginal ultrasound baseline . Key Exclusion Criteria 1 . Blastocyst stage frozenthaw transfer 2 . Clinically significant abnormality ECG , vital sign , physical examination clinical laboratory result 3 . Severe endometriosis and/or adenomyosis risk ovarian hyper stimulation syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>IVF</keyword>
	<keyword>ICSI</keyword>
</DOC>